论文部分内容阅读
欧洲委员会批准Vibativ(telavancin hydrochloride)用于在无合适的其他选择时,治疗已确诊或可疑由耐甲氧西林金黄色葡萄球菌(MRSA)引起的医院获得性肺炎成人患者,包括呼吸机相关性肺炎。
The European Commission approved Vibativ® (telavancin hydrochloride) for the treatment of hospitalized patients with confirmed or suspected hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) in the absence of other options, including ventilator-related pneumonia.